Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Drug Susceptibility Testing of Mycobacterium Simiae: An Emerging Pathogen in Iran

Author(s): Mohammad Javad Nasiri*, Sirus Amini, Zahra Nikpor, Samaneh Arefzadeh, Seyyed Mohammad Javad Mousavi and Hossein Goudarzi

Volume 21, Issue 4, 2021

Published on: 27 July, 2020

Page: [619 - 622] Pages: 4

DOI: 10.2174/1871526520999200727114148

Price: $65

Abstract

Introduction: Mycobacterium simiae is an emerging pathogen in Iran and little is known about drug susceptibility patterns of this pathogen.

Materials and Methods: Twenty-five clinical isolates of M. simiae from 80 patients with confirmed NTM pulmonary disease were included in this study. For drug susceptibility testing (DST), proportional and broth microdilution methods were used according to the clinical and laboratory standards institute (CLSI) guideline.

Results: All clinical isolates of M. simiae were resistant to isoniazid, rifampicin, ethambutol, streptomycin, amikacin, kanamycin, ciprofloxacin, and clarithromycin. They also were highly resistant to ofloxacin (80%). Susceptibility to ofloxacin was only noted in the 5 isolates.

Conclusion: Clinical isolates of M. simiae were multidrug-resistant, and had different drug susceptibility patterns than previously published studies. DST results can assist in selecting more appropriate treatment regimens. Newer drugs with proven clinical efficacy correlating with in vitro susceptibility should be substituted with first- and second-line anti-TB drug testing.

Keywords: Mycobacterium simiae, drug resistance, Iran, pulmonary disease, susceptibility, anti-TB drug testing.

[1]
Prevots, D.R.; Marras, T.K. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin. Chest Med., 2015, 36(1), 13-34.
[http://dx.doi.org/10.1016/j.ccm.2014.10.002] [PMID: 25676516]
[2]
Nasiri, M.J.; Dabiri, H.; Darban-Sarokhalil, D.; Shahraki, H.A. Prevalence of non-tuberculosis mycobacterial infections among tuberculosis suspects in Iran: systematic review and meta-analysis. PLoS One, 2015, 10(6), e0129073.
[http://dx.doi.org/10.1371/journal.pone.0129073] [PMID: 26052701]
[3]
Nasiri, M.J.; Dabiri, H.; Fooladi, A.A.I.; Amini, S.; Hamzehloo, G.; Feizabadi, M.M. High rates of nontuberculous mycobacteria isolation from patients with presumptive tuberculosis in Iran. New Microbes New Infect., 2017, 21, 12-17.
[http://dx.doi.org/10.1016/j.nmni.2017.08.008] [PMID: 29188063]
[4]
Hamieh, A.; Tayyar, R.; Kanj, S. Growing Knowledge about Mycobacterium simiae from Two Recent Studies. Antimicrob. Agents Chemother., 2018, 62(11), e01454-e18.
[http://dx.doi.org/10.1128/AAC.01454-18] [PMID: 30355746]
[5]
Hashemi-Shahraki, A.; Darban-Sarokhalil, D.; Heidarieh, P.; Feizabadi, M.M.; Deshmir-Salameh, S.; Khazaee, S.; Alavi, S.M. Mycobacterium simiae: a possible emerging pathogen in Iran. Jpn. J. Infect. Dis., 2013, 66(6), 475-479.
[http://dx.doi.org/10.7883/yoken.66.475] [PMID: 24270133]
[6]
Philley, J.V.; Griffith, D.E. Treatment of slowly growing mycobacteria. Clin. Chest Med., 2015, 36(1), 79-90.
[http://dx.doi.org/10.1016/j.ccm.2014.10.005] [PMID: 25676521]
[7]
van Ingen, J.; Totten, S.E.; Heifets, L.B.; Boeree, M.J.; Daley, C.L. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int. J. Antimicrob. Agents, 2012, 39(2), 173-176.
[http://dx.doi.org/10.1016/j.ijantimicag.2011.09.019] [PMID: 22099521]
[8]
van Ingen, J.; van der Laan, T.; Dekhuijzen, R.; Boeree, M.; van Soolingen, D. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int. J. Antimicrob. Agents, 2010, 35(2), 169-173.
[http://dx.doi.org/10.1016/j.ijantimicag.2009.09.023] [PMID: 20006470]
[9]
Griffith, D.E.; Aksamit, T.; Brown-Elliott, B.A.; Catanzaro, A.; Daley, C.; Gordin, F.; Holland, S.M.; Horsburgh, R.; Huitt, G.; Iademarco, M.F.; Iseman, M.; Olivier, K.; Ruoss, S.; von Reyn, C.F.; Wallace, R.J., Jr; Winthrop, K. ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med., 2007, 175(4), 367-416.
[http://dx.doi.org/10.1164/rccm.200604-571ST] [PMID: 17277290]
[10]
Kent, P.T.; Kubica, G.P.; Control, C.D. Public health mycobacteriology: a guide for the level III laboratory; US Department of Health and Human Services, Public Health Service, Centers for Disease Control, 1985.
[11]
Telenti, A.; Marchesi, F.; Balz, M.; Bally, F.; Böttger, E.C.; Bodmer, T. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J. Clin. Microbiol., 1993, 31(2), 175-178.
[http://dx.doi.org/10.1128/JCM.31.2.175-178.1993] [PMID: 8381805]
[12]
Rogall, T.; Flohr, T.; Böttger, E.C. Differentiation of Mycobacterium species by direct sequencing of amplified DNA. J. Gen. Microbiol., 1990, 136(9), 1915-1920.
[http://dx.doi.org/10.1099/00221287-136-9-1915] [PMID: 2283506]
[13]
Woods, G.L.; Lin, S-Y.G.; Desmond, E.P. Susceptibility test methods: mycobacteria, nocardia, and other actinomycetes.Manual of Clinical Microbiology, 10th ed; American Society of Microbiology, 2011, pp. 1215-1238.
[14]
Nasiri, M.J.; Rezaei, F.; Zamani, S.; Darban-Sarokhalil, D.; Fooladi, A.A.; Shojaei, H.; Feizabadi, M.M. Drug resistance pattern of Mycobacterium tuberculosis isolates from patients of five provinces of Iran. Asian Pac. J. Trop. Med., 2014, 7(3), 193-196.
[http://dx.doi.org/10.1016/S1995-7645(14)60019-5] [PMID: 24507638]
[15]
van Ingen, J.; Boeree, M.J.; Dekhuijzen, P.N.; van Soolingen, D. Clinical relevance of Mycobacterium simiae in pulmonary samples. Eur. Respir. J., 2008, 31(1), 106-109.
[http://dx.doi.org/10.1183/09031936.00076107] [PMID: 18166593]
[16]
Hamieh, A.; Tayyar, R.; Tabaja, H.; E L Zein, S.; Bou Khalil, P.; Kara, N.; Kanafani, Z.A.; Kanj, N.; Bou Akl, I.; Araj, G.; Berjaoui, G.; Kanj, S.S. Emergence of Mycobacterium simiae: A retrospective study from a tertiary care center in Lebanon. PLoS One, 2018, 13(4), e0195390.
[http://dx.doi.org/10.1371/journal.pone.0195390] [PMID: 29617415]
[17]
Nasiri, M.J.; Heidary, M.; Azimi, T.; Goudarzi, H.; Tabarsi, P.; Sarokhalil, D.D.; Feizabadi, M.M. Mycobacterium simiae pulmonary disease in Iran: systematic review and meta-analysis. New Microbes New Infect., 2018, 26, 118-123.
[http://dx.doi.org/10.1016/j.nmni.2018.09.008] [PMID: 30370055]
[18]
Azadi, D.; Shojaei, H.; Pourchangiz, M.; Dibaj, R.; Davarpanah, M.; Naser, A.D. Species diversity and molecular characterization of nontuberculous mycobacteria in hospital water system of a developing country, Iran. Microb. Pathog., 2016, 100, 62-69.
[http://dx.doi.org/10.1016/j.micpath.2016.09.004] [PMID: 27616445]
[19]
Khosravi, A.D.; Hashemi Shahraki, A.; Hashemzadeh, M.; Sheini Mehrabzadeh, R.; Teimoori, A. Prevalence of non-tuberculous mycobacteria in hospital waters of major cities of Khuzestan Province, Iran. Front. Cell. Infect. Microbiol., 2016, 6, 42.
[http://dx.doi.org/10.3389/fcimb.2016.00042] [PMID: 27148491]
[20]
Coolen-Allou, N.; Touron, T.; Belmonte, O.; Gazaille, V.; Andre, M.; Allyn, J.; Picot, S.; Payet, A.; Veziris, N. Clinical, radiological, and microbiological characteristics of Mycobacterium simiae infection in 97 patients. Antimicrob. Agents Chemother., 2018, 62(7), e00395-e18.
[http://dx.doi.org/10.1128/AAC.00395-18] [PMID: 29760130]

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy